Health Economics & Market Access

Health Economic Modeling

Health Economics & Market Access

Health Economic Modeling

Biosense Webster, Inc. expands patient access to our advanced technologies by articulating the clinical and economic value associated with our innovative products through peer-reviewed health economic modeling.

Summary of Economic Evaluation of RFCA

Economic Evaluation of RFCA

An economic model utilizing results from the PRECEPT trial was developed to quanitfy the monetary impact of radiofrequency catheter ablation (RFCA) versus medical therapy (MT) for the treatment of persistent atrial fibrillation (PsAF). 

The model demonstrated that RFCA was associated with an annual cost-offset and found that the break-even point occured at: 

  • 4.2 years for Medicare payers
  • 5.1 years for self-insured employer payers
  • 5.9 years for commercial payers

Read Summary

Read Article

Summary of AF ablation cost minimization model

Cost Minimization Analysis of Catheter Ablation for Paroxysmal AF Ablation

Osorio, Jose, et al. J Comp E_ Res. 2019:8.4 241-249.

This health economic model evaluated the costs of paroxysmal AF ablation with the THERMOCOOL SMARTTOUCH® Catheter (ST), THERMOCOOL SMARTTOUCH® SF Catheter (SF) and Arctic Front Advance™ Cardiac Cryoablation Catheter (CB).

Study outcomes:

  • Expected savings for ST compared to CB was $8,206 (inpatient), $3,859 (outpatient) and $4,494 (hospital mix)
  • Expected savings for ST compared to SF was $1,763 (inpatient), $1,405 (outpatient) and $1,488 (hospital mix)

Read Article